Biocytogen Pharmaceuticals Beijing Co. Ltd. has announced its unaudited consolidated results for the six months ended June 30, 2025. The company reported a significant increase in revenue, which rose by 51.3% to RMB 620.963 million compared to RMB 410.499 million for the same period in 2024. The gross profit also saw a 51.2% increase, reaching RMB 461.949 million from RMB 305.493 million in the previous year. The company reported a profit before taxation of RMB 59.620 million, a notable improvement from the loss of RMB 47.077 million in the same period of 2024. The profit for the period attributable to equity shareholders was RMB 47.999 million, in contrast to a loss of RMB 50.673 million in the previous year. The increase in revenue was driven by significant growth in several service lines, particularly in pre-clinical pharmacology and efficacy evaluation, which generated RMB 155.031 million, and animal models selling, which contributed RMB 274.426 million. Other areas such as antibody development also saw an increase, with revenue reaching RMB 162.863 million. Biocytogen Pharmaceuticals continues its focus on providing gene-editing services, pre-clinical pharmacology and efficacy evaluation services, and selling animal models, despite not having any products approved for commercial sale. The company did not provide an outlook or guidance for future periods.